{"id":10828,"date":"2025-05-20T19:17:38","date_gmt":"2025-05-20T23:17:38","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=10828"},"modified":"2025-05-20T19:17:38","modified_gmt":"2025-05-20T23:17:38","slug":"fda-delays-biohavens-approval-decision-for-rare-disease-drug-troriluzole","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/fda-delays-biohavens-approval-decision-for-rare-disease-drug-troriluzole\/","title":{"rendered":"FDA Delays Biohaven\u2019s Approval Decision for Rare Disease Drug Troriluzole"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">The U.S. Food and Drug Administration (FDA) has postponed its decision on Biohaven Pharmaceuticals\u2019 lead drug candidate, troriluzole, a potential treatment for a group of rare neurological conditions that damage nerve function. The company had anticipated a regulatory verdict by the end of September, following the completion of late-stage clinical trials. However, Biohaven announced that the FDA now requires additional time and input from an independent advisory committee, a move that adds uncertainty to the review process.<\/span><br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\n<span style=\"font-weight: 400;\">This development contradicts Biohaven\u2019s previous communication. In its recent earnings report, the company stated that FDA officials had not mentioned the possibility of convening an advisory panel\u2014a step usually taken when the agency has remaining questions about the safety, efficacy, or overall benefit-risk profile of a drug under review.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Troriluzole is Biohaven\u2019s most advanced clinical candidate and is designed to metabolize into a molecule already approved in the U.S. and Europe to treat amyotrophic lateral sclerosis (ALS). Biohaven is positioning the drug as a therapy for a wider range of conditions, from the rare spinocerebellar ataxia (SCA) to more common illnesses like obsessive-compulsive disorder (OCD).<\/span><\/p>\n<h3><b>Key Developments and Market Impact<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Regulatory setback in the U.S.<\/b><span style=\"font-weight: 400;\">: The FDA\u2019s request for an advisory committee adds months to the review process and suggests increased regulatory scrutiny.<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Unexpected reversal<\/b><span style=\"font-weight: 400;\">: Just days before the announcement, Biohaven reported no signs from the FDA of needing such a meeting.<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>European withdrawal<\/b><span style=\"font-weight: 400;\">: In March, Biohaven withdrew its marketing application for troriluzole in Europe after the EMA indicated likely rejection and declined to grant a special designation with economic benefits.<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Market reaction<\/b><span style=\"font-weight: 400;\">: The European decision alone led to a $400 million loss in Biohaven\u2019s market value. Combined with other setbacks, the stock is down roughly 15% over the past six months.<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Investor concerns<\/b><span style=\"font-weight: 400;\">: Analysts such as Leonid Timashev of RBC Capital Markets say the new delay raises doubts about the overall regulatory outlook for troriluzole and increases the chances of a rejection.<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Staffing issues at the FDA<\/b><span style=\"font-weight: 400;\">: Some believe the delay may also be partly attributed to internal staffing shortages at the FDA following recent layoffs.<\/span><\/li>\n<\/ul>\n<p><script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\n<span style=\"font-weight: 400;\">If successful, troriluzole would become the first approved treatment for SCA and could mark a turning point for Biohaven, which has not brought a new therapy to market since it sold its migraine drug portfolio to Pfizer for $12 billion in 2022. The company has indicated it plans to reapply in Europe and remains committed to advancing its rare disease pipeline.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has postponed its decision on Biohaven Pharmaceuticals\u2019 lead drug candidate, troriluzole, a potential treatment for a group of rare neurological conditions that damage nerve function. The company had anticipated a regulatory verdict by the end of September, following the completion of late-stage clinical trials. However, Biohaven announced that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10829,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[],"class_list":{"0":"post-10828","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-regulatory"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=10828"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10828\/revisions"}],"predecessor-version":[{"id":10830,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/10828\/revisions\/10830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/10829"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=10828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=10828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=10828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}